The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits

Ketamine is a rapidly acting antidepressant in patients with treatment-resistant depression (TRD). Although the mechanisms underlying these effects are not fully established, inquiry to date has focused on the triggering of synaptogenesis transduction pathways via glutamatergic mechanisms. Preclinical data suggest that blockade of metabotropic glutamate (mGlu2/3) receptors shares many overlapping features and mechanisms with ketamine and may also provide rapid efficacy for TRD patients. Central dopamine circuitry is recognized as an end target for mood regulation and hedonic valuation and yet has been largely neglected in mechanistic studies of antidepressant-relevant effects of ketamine. Herein, we evaluated the changes in dopaminergic neurotransmission after acute administration of ketamine and the mGlu2/3 receptor antagonist LY341495 [(2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid ] in preclinical models using electrophysiologic, neurochemical, and behavioral endpoints. When given acutely, both ketamine and LY341495, but not the selective serotonin reuptake inhibitor (SSRI) citalopram, increased the number of spontaneously active dopamine neurons in the ventral tegmental area (VTA), increased extracellular levels of dopamine in the nucleus accumbens and prefrontal cortex, and enhanced the locomotor stimulatory effects of the dopamine D2/3 receptor agonist quinpirole. Further, both ketamine and LY341495 reduced immobility time in the tail-suspension assay in CD1 mice, which are relatively resistant to SSRI antidepressants. Both the VTA neuronal activation and the antidepressant phenotype induced by ketamine and LY341495 were attenuated by the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo- (9CI)-benzo[f]quinoxaline-7-sulfonamide, indicating AMPA-dependent effects. These findings provide another overlapping mechanism of action of ketamine and mGlu2/3 receptor antagonism that differentiates them from conventional antidepressants and thus support the potential rapidly acting antidepressant actions of mGlu2/3 receptor antagonism in patients.

[1]  Jodi L. Smith,et al.  In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonist , 2017, Neuropharmacology.

[2]  S. Chaki,et al.  The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN , 2016, Neuropsychopharmacology.

[3]  Oliver H. Miller,et al.  Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition , 2016, Neuropharmacology.

[4]  T. Svensson,et al.  Ketamine-like effects of a combination of olanzapine and fluoxetine on AMPA and NMDA receptor-mediated transmission in the medial prefrontal cortex of the rat , 2015, European Neuropsychopharmacology.

[5]  R. Shelton,et al.  Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies , 2015, Journal of clinical psychopharmacology.

[6]  J. Roiser,et al.  Neural correlates of change in major depressive disorder anhedonia following open-label ketamine , 2015, Journal of psychopharmacology.

[7]  Yixing Gao,et al.  Dopamine D2/D3 but not dopamine D1 receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test , 2015, Behavioural Brain Research.

[8]  J. Krystal,et al.  Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. , 2015, Annual review of medicine.

[9]  A. Schatzberg,et al.  Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? , 2015, Neuropsychopharmacology.

[10]  A. Grace,et al.  Restoring Mood Balance in Depression: Ketamine Reverses Deficit in Dopamine-Dependent Synaptic Plasticity , 2014, Biological Psychiatry.

[11]  D. H. Root,et al.  Glutamate neurons within the midbrain dopamine regions , 2014, Neuroscience.

[12]  J. Roiser,et al.  Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression , 2014, Translational Psychiatry.

[13]  J. Cheer,et al.  Local control of striatal dopamine release , 2014, Front. Behav. Neurosci..

[14]  M. Giurfa,et al.  The tarsal taste of honey bees: behavioral and electrophysiological analyses , 2014, Front. Behav. Neurosci..

[15]  N. Sousa,et al.  Serotonin 2C receptor antagonists induce fast-onset antidepressant effects , 2014, Molecular Psychiatry.

[16]  M. Vinberg,et al.  Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials , 2013, Nordic journal of psychiatry.

[17]  D. Nutt,et al.  Anhedonia revisited: Is there a role for dopamine-targeting drugs for depression? , 2013, Journal of psychopharmacology.

[18]  Aaron S. Andalman,et al.  Dopamine neurons modulate neural encoding and expression of depression-related behaviour , 2012, Nature.

[19]  K. Deisseroth,et al.  Rapid regulation of depression-related behaviors by control of midbrain dopamine neurons , 2012, Nature.

[20]  J. Krystal,et al.  Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. , 2012, Schizophrenia bulletin.

[21]  K. Manaye,et al.  Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar–Kyoto rats , 2012, Neuroscience.

[22]  R. Duman,et al.  mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade. , 2012, The international journal of neuropsychopharmacology.

[23]  Nanxin Li,et al.  Signaling pathways underlying the rapid antidepressant actions of ketamine , 2012, Neuropharmacology.

[24]  S. Chaki,et al.  Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression , 2011, Behavioural Brain Research.

[25]  E. Kavalali,et al.  NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses , 2011, Nature.

[26]  S. Otani,et al.  Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway , 2011, Neuroscience.

[27]  J. Weiss,et al.  Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum. , 2011, The international journal of neuropsychopharmacology.

[28]  M. Millan,et al.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs , 2011, Neurotherapeutics.

[29]  Francois Pomerleau,et al.  Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex , 2010, Journal of neurochemistry.

[30]  S. Chaki,et al.  AMPA receptor mediates mGlu 2/3 receptor antagonist-induced dopamine release in the rat nucleus accumbens shell , 2010, Neurochemistry International.

[31]  Nanxin Li,et al.  mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists , 2010, Science.

[32]  J. Price,et al.  Neurocircuitry of Mood Disorders , 2010, Neuropsychopharmacology.

[33]  G. Sanacora,et al.  Targeting glial physiology and glutamate cycling in the treatment of depression. , 2009, Biochemical pharmacology.

[34]  P. Blier,et al.  Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. , 2009, Journal of psychiatry & neuroscience : JPN.

[35]  C. Swanson,et al.  The MCH1 receptor antagonist SNAP 94847 induces sensitivity to dopamine D2/D3 receptor agonists in rats and mice. , 2009, European journal of pharmacology.

[36]  Guang Chen,et al.  Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors , 2008, Biological Psychiatry.

[37]  L. Iversen.  The Monoamine Hypothesis of Depression , 2008 .

[38]  J. Ballenger.  A Randomized Trial of an N-methyl-d-aspartate Antagonist in Treatment-Resistant Major DepressionZarate CA, Singh JB, Carlson PJ, et al (NIH, Bethesda, Md) Arch Gen Psychiatry 63:856–864, 2006§ , 2008 .

[39]  J. Kehr,et al.  Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors , 2007, Journal of psychopharmacology.

[40]  B. Moghaddam,et al.  NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons , 2007, The Journal of Neuroscience.

[41]  James P. Herman,et al.  Role of the ventral subiculum in stress integration , 2006, Behavioural Brain Research.

[42]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[43]  E. Nisenbaum,et al.  A role for AMPA receptors in mood disorders. , 2006, Biochemical pharmacology.

[44]  D. Kupfer,et al.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. , 2006, The American journal of psychiatry.

[45]  K. Perry,et al.  Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat , 2004, Neuropharmacology.

[46]  P. Skolnick,et al.  Enhancement of Antidepressant Potency by a Potentiator of AMPA Receptors , 2003, Cellular and Molecular Neurobiology.

[47]  D. Wong,et al.  Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex , 2002, Psychopharmacology.

[48]  P. D’Aquila,et al.  The role of dopamine in the mechanism of action of antidepressant drugs. , 2000, European journal of pharmacology.

[49]  D. Wong,et al.  Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex , 2000, Neuropsychopharmacology.

[50]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[51]  D. Cyril D’Souza,et al.  Interactive effects of subanesthetic ketamine and haloperidol in healthy humans , 1999, Psychopharmacology.

[52]  I. Lucki,et al.  Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test , 1998, Psychopharmacology.

[53]  P. Ornstein,et al.  LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors , 1998, Neuropharmacology.

[54]  Yong Li,et al.  Effects of the AMPA receptor antagonist NBQX on the development and expression of behavioral sensitization to cocaine and amphetamine , 1997, Psychopharmacology.

[55]  P. D’Aquila,et al.  Dizocilpine prevents the enhanced locomotor response to quinpirole induced by repeated electroconvulsive shock. , 1997, European journal of pharmacology.

[56]  P. Willner.  The mesolimbic dopamine system as a target for rapid antidepressant action , 1997, International clinical psychopharmacology.

[57]  N. Andreasen.  Improvement of negative symptoms: concepts, definition and assessment , 1997, International clinical psychopharmacology.

[58]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[59]  A. Ceci,et al.  Non-competitive N-methyl-d-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons , 1990, Neuroscience Letters.

[60]  P. Skolnick,et al.  Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. , 1990, European journal of pharmacology.

[61]  P. Beardsley,et al.  Evaluation of antagonists of the discriminative stimulus and response rate effects of phencyclidine. , 1988, The Journal of pharmacology and experimental therapeutics.

[62]  A. Grace,et al.  Intracellular and extracellular electrophysiology of nigral dopaminergic neurons—1. Identification and characterization , 1983, Neuroscience.

[63]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[64]  A. Phillips,et al.  Increased intracranial self-stimulation in rats after long-term administration of desipramine. , 1981, Science.

[65]  H. Fibiger,et al.  Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. , 1981, European journal of pharmacology.

[66]  S. Tufik,et al.  Does REM sleep deprivation induce a supersensitivity of dopaminergic receptors in the rat brain? , 1978, Pharmacology.

[67]  R. Porsolt,et al.  Behavioral despair in mice: a primary screening test for antidepressants. , 1977, Archives internationales de pharmacodynamie et de therapie.

[68]  A. Phillips,et al.  Long-term deficits in stimulation-induced behaviors and self-stimulation after 6-hydroxydopamine administration in rats. , 1976, Behavioral biology.

[69]  James L Olds,et al.  Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. , 1954, Journal of comparative and physiological psychology.